Literature DB >> 11108720

Ribosomal S6 kinase 2 inhibition by a potent C-terminal repressor domain is relieved by mitogen-activated protein-extracellular signal-regulated kinase kinase-regulated phosphorylation.

K A Martin1, S S Schalm, A Romanelli, K L Keon, J Blenis.   

Abstract

Ribosomal S6 kinase 2 (S6K2) is a recently identified serine/threonine protein kinase that phosphorylates the 40 S ribosomal protein S6 in vitro. S6K2 is highly homologous to S6K1 in the core kinase and linker regulatory domains but differs from S6K1 in the N- and C-terminal regions and is differently localized primarily to the nucleus because of a C-terminal nuclear localization signal unique to S6K2. We have recently demonstrated that S6K2 is regulated similarly to S6K1 by the mammalian target of rapamycin pathway and by multiple PI3-K pathway effectors in vivo. However, deletion of the C-terminal domain of S6K2 enhances kinase activity, whereas analogous deletion of S6K1 is inhibitory. Here, we characterize the S6K2 C-terminal motifs that confer this differential regulation. We demonstrate that the inhibitory effects of the S6K2 C-terminal domain are only partly attributable to the nuclear localization signal but that three C-terminal proline-directed potential mitogen-activated protein kinase phosphorylation sites are critical mediators of this inhibitory effect. Site-specific mutation of these sites to alanine completely desensitizes S6K2 to activating inputs, whereas mutation to aspartic acid to mimic phosphorylation results in an activated enzyme which is hypersensitive to activating inputs. Pretreatment of cells with the mitogen-activated protein-extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited S6K2 activation to a greater extent than S6K1. Furthermore, S6K2 mutants with C-terminal deletion or acidic phosphorylation site mutations displayed greatly reduced U0126 sensitivity. Thus, MEK-dependent inputs to C-terminal phosphorylation sites appear to be essential for relief of S6K2 inhibition but less critical for activation of S6K1. These data suggest a mechanism by which weak PI3-K agonists can regulate S6 phosphorylation and selective translation in the presence of mitogen-activated protein kinase signaling.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11108720     DOI: 10.1074/jbc.M009972200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation.

Authors:  Sejeong Shin; Laura Wolgamott; Yonghao Yu; John Blenis; Sang-Oh Yoon
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

2.  Identification of S6K2 as a centrosome-located kinase.

Authors:  Rossella Rossi; John M Pester; Mitch McDowell; Samuela Soza; Alessandra Montecucco; Kay K Lee-Fruman
Journal:  FEBS Lett       Date:  2007-07-30       Impact factor: 4.124

3.  FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2.

Authors:  Olivier E Pardo; Claudia Wellbrock; Umme K Khanzada; Muriel Aubert; Imanol Arozarena; Sally Davidson; Frances Bowen; Peter J Parker; V V Filonenko; Ivan T Gout; Neil Sebire; Richard Marais; Julian Downward; Michael J Seckl
Journal:  EMBO J       Date:  2006-06-29       Impact factor: 11.598

4.  S6 kinase 2 potentiates interleukin-3-driven cell proliferation.

Authors:  Rebecca Cruz; Lee Hedden; Derek Boyer; Michael G Kharas; David A Fruman; Kay K Lee-Fruman
Journal:  J Leukoc Biol       Date:  2005-10-04       Impact factor: 4.962

5.  Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK.

Authors:  Peter Kubiniok; Hugo Lavoie; Marc Therrien; Pierre Thibault
Journal:  Mol Cell Proteomics       Date:  2017-02-10       Impact factor: 5.911

6.  Identification of the S6 kinase activity stimulated in quiescent brine shrimp embryos upon entry to preemergence development as p70 ribosomal protein S6 kinase: isolation of Artemia franciscana p70S6k cDNA.

Authors:  J Santiago; T W Sturgill
Journal:  Biochem Cell Biol       Date:  2001       Impact factor: 3.626

7.  Development of monoclonal antibodies specific to ribosomal protein S6 kinase 2.

Authors:  Lilia Savinska; Oleksandr Skorokhod; Olga Klipa; Ivan Gout; Valeriy Filonenko
Journal:  Hybridoma (Larchmt)       Date:  2012-08

8.  Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase.

Authors:  X Wang; W Li; M Williams; N Terada; D R Alessi; C G Proud
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

9.  Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Authors:  Michael G Kharas; Matthew R Janes; Vanessa M Scarfone; Michael B Lilly; Zachary A Knight; Kevan M Shokat; David A Fruman
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

10.  Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy.

Authors:  Julie R McMullen; Tetsuo Shioi; Li Zhang; Oleg Tarnavski; Megan C Sherwood; Adam L Dorfman; Sarah Longnus; Mario Pende; Kathleen A Martin; John Blenis; George Thomas; Seigo Izumo
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.